Highlights
- In a large cohort of 2,192 critically ill patients with obesity, 13.5% required kidney replacement therapy (KRT).
- The 90-day mortality rate for obese patients requiring KRT was 49.8%, compared to 18.9% for those not requiring the intervention.
- Multivariate Cox analysis confirmed KRT as an independent predictor of increased mortality in this population.
- Over a 15-year period (2009–2024), the incidence of acute kidney injury (AKI) in obese ICU patients significantly decreased.
Introduction: The Intersection of Obesity and Critical Illness
Obesity has reached pandemic proportions, presenting a significant challenge to modern intensive care medicine. Patients with obesity (defined as a body mass index [BMI] ≥ 30 kg/m2) are disproportionately represented in the intensive care unit (ICU) and are at an inherently higher risk for various complications, including chronic kidney disease and acute kidney injury (AKI). While some studies have suggested an ‘obesity paradox’—where higher BMI might offer a survival advantage in certain critical conditions—the specific impact of kidney replacement therapy (KRT) on this population remains a subject of intense debate.
The physiological changes associated with obesity, such as altered drug pharmacokinetics, increased intra-abdominal pressure, and a baseline pro-inflammatory state, complicate the management of AKI. Clinicians often face challenges in determining the optimal timing, dosing, and modality of KRT for these patients. This study by Monet et al., published in Intensive Care Medicine, provides a much-needed longitudinal perspective on how KRT affects short- and long-term outcomes in obese patients and how these trends have evolved over the last 15 years.
Study Design and Methodology
The researchers conducted a retrospective observational cohort study at a medico-surgical ICU between 2009 and 2024. The study included all consecutive patients with obesity, defined by a BMI of 30 kg/m2 or higher. AKI was categorized according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, which standardize the definition based on serum creatinine levels and urine output.
The primary endpoint was 90-day mortality. Secondary endpoints included 1-year mortality, trends in AKI and KRT incidence over the 15-year study period, and variations in the Simplified Acute Physiology Score (SAPS II). To ensure robust findings, the team utilized Kaplan-Meier survival curves and a multivariate Cox proportional hazards model to adjust for potential confounders, such as age, comorbidities, and severity of illness at admission.
Key Findings: A Deep Dive into the Data
Short- and Long-Term Mortality Outcomes
The study analyzed 2,192 patients with obesity. Within this group, 295 patients (13.5%) underwent KRT during their ICU stay. The results revealed a stark contrast in survival between the two groups. The 90-day mortality rate was 49.8% (95% CI [44.1–55.5]) in the KRT group, whereas the non-KRT group experienced a significantly lower mortality rate of 18.9% (95% CI [17.2–20.7], p < 0.0001). This represents a nearly three-fold increase in the risk of death at three months for those requiring renal support.
Long-term data mirrored these findings, with 1-year mortality remaining substantially higher in the KRT group. Even after adjusting for baseline severity using the SAPS II score and other clinical variables, the multivariate analysis confirmed that the need for KRT was independently associated with an increased risk of 90-day mortality. This suggests that the requirement for KRT is not merely a marker of systemic illness but is itself a critical prognostic factor in the obese population.
15-Year Longitudinal Trends
One of the most intriguing aspects of this study is the analysis of temporal trends. From 2009 to 2024, the researchers observed a statistically significant decrease in the incidence of AKI among critically ill obese patients (p < 0.001). This trend may reflect improvements in early ICU management, such as more judicious fluid resuscitation, better hemodynamic monitoring, and increased awareness of nephrotoxic medications.
Despite the decrease in AKI incidence, the mortality risk associated with KRT remained high throughout the study period. The incidence of KRT itself did not show the same pronounced decline as AKI, suggesting that while we are preventing mild to moderate kidney injury more effectively, the subgroup of patients who progress to severe, life-threatening renal failure remains a persistent clinical challenge.
Expert Commentary and Clinical Implications
The Complexity of KRT in Obesity
The independent association between KRT and mortality in obese patients raises important questions about biological plausibility and clinical management. Obesity is often associated with a ‘hyperfiltrating’ state and increased metabolic demand, which may influence how AKI develops and recovers. Furthermore, the technical aspects of KRT in obese patients—such as obtaining reliable vascular access and ensuring adequate solute clearance—can be more difficult.
There is also the consideration of ‘dose-capping.’ In many ICUs, KRT doses are calculated based on weight. However, using actual body weight in morbidly obese patients can lead to excessive clearance of medications and nutrients, while using ideal body weight might result in under-dialysis. The high mortality observed in this study suggests that our current ‘one-size-fits-all’ or simplified weight-based approaches to KRT may not be sufficient for the unique physiology of the obese patient.
Study Limitations and Generalizability
As an observational retrospective study, there are inherent limitations. While the multivariate analysis adjusted for many variables, unmeasured confounding—such as the specific cause of AKI or the exact timing of KRT initiation—could influence the results. The study was also conducted in a single center, which may limit the generalizability of the findings to different ICU settings or geographic regions with different obesity phenotypes.
However, the 15-year duration and the large sample size provide significant weight to the findings. The consistency of the mortality gap between the KRT and non-KRT groups over a decade and a half suggests a robust biological signal rather than a transient clinical fluke.
Conclusion: Moving Toward Precision Management
The study by Monet et al. serves as a critical call to action for intensive care and nephrology specialists. While the overall incidence of AKI in the obese ICU population is declining, those who require KRT face a grim prognosis. The 49.8% 90-day mortality rate highlights that we have yet to optimize the management of severe renal failure in this specific demographic.
Future research must move beyond observational data toward prospective, randomized controlled trials that specifically target the obese population. These studies should investigate the optimal timing of KRT initiation, personalized dosing strategies that account for body composition rather than just total weight, and the impact of different KRT modalities on long-term renal recovery. Until then, clinicians should approach KRT in obese patients with heightened vigilance, recognizing it as a high-stakes intervention that requires meticulous multidisciplinary coordination.
References
Monet C, Bouziane J, Pensier J, Aarab Y, Capdevila M, Lakbar I, Muller L, Roger C, De Jong A, Jaber S. Short- and long-term outcomes and 15-year time trends of kidney replacement therapy in critically ill patients with obesity: an observational cohort. Intensive Care Med. 2025 Jul;51(7):1320-1330. doi: 10.1007/s00134-025-07990-2. Epub 2025 Jun 30. PMID: 40586797.